News: Industry

Articles

616bfc3dd4492f5672cce84a1653fd6f2eaa10cefacae54c9e1965cca1add0a8
3 Sep 2026 Industry

AbbVie Pays $10.9 Billion for Apogee, Bringing Long-Acting Atopic Dermatitis Candidate Into Its Pipeline

AbbVie completes its $10.9 billion acquisition of Apogee Therapeutics, adding zumilokibart and other promising immunology treatments to its …

031bf92e99040720cb8b6e1cdfe3276ffa0f6a2b5623dcd9b76a9818a10eb280
24 Jul 2026 Industry

Sanofi Stops Amlitelimab Development in Atopic Dermatitis After Reviewing Phase 3 Evidence

Sanofi ends development of amlitelimab for atopic dermatitis after concluding that available efficacy and safety data do not …